Challenges with modelling anxiety disorders: a possible hindrance for drug discovery

Expert Opin Drug Discov. 2018 Apr;13(4):279-281. doi: 10.1080/17460441.2018.1418321. Epub 2017 Dec 18.

Authors

Florian Freudenberg¹, Aet O'Leary^{1

2}, Daniele C Aguiar^{1

3}, David A Slattery¹

Affiliations

¹ a Department of Psychiatry, Psychosomatic Medicine and Psychotherapy , University Hospital Frankfurt , Frankfurt , Germany.
² b Division of Neuropsychopharmacology, Department of Psychology , University of Tartu , Tartu , Estonia.
³ c Department of Pharmacology , Universidade Federal de Minas Gerais , Belo Horizonte , Brazil.

PMID: 29240521
DOI: 10.1080/17460441.2018.1418321

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Anxiety Agents / pharmacology*
Anxiety Disorders / drug therapy*
Anxiety Disorders / physiopathology
Disease Models, Animal
Drug Design
Drug Discovery / methods*
Humans

Substances

Anti-Anxiety Agents